There will be a new way to file Zofran lawsuits that claim the pharmaceutical giant GlaxoSmithKline’s anti-nausea drug Zofran can cause birth defects. More than 260 families claim that GlaxoSmithKline (GSK) failed to warn them of Zofran’s alleged risks, in spite of the drug’s status as America’s top-selling morning sickness treatment. Several plaintiffs have already […]
There will be a new way to file Zofran lawsuits that claim the pharmaceutical giant GlaxoSmithKline’s anti-nausea drug Zofran can cause birth defects. More than 260 families claim that GlaxoSmithKline (GSK) failed to warn them of Zofran’s alleged risks, in spite of the drug’s status as America’s top-selling morning sickness treatment.
Several plaintiffs have already used the short form complaint to file Zofran birth defect lawsuits to ensure their voices are heard in a growing litigation against GSK. Instead of writing lengthy individual complaints, parents will soon have the opportunity to work from a “Master Complaint,” which combines all the core allegations aimed against Zofran’s manufacturer, The Legal Examiner reports.
A mother from Sandusky, Ohio, claims her son, born in 2006, developed a battery of heart and facial defects after continuous prenatal exposure to Zofran. The child lives with an atrial septal defect, ventricular septal defect and cleft palate, according to the plaintiffs’ Short Form Complaint. The mother also maintains her child has suffered “issues with vision and hearing” that are probably a result of the cleft palate. This was one of the first lawsuits submitted using the short form complaint.
Zofran has been approved for use in post-operative surgery patients, or patients undergoing certain cancer treatments, as an anti-nausea medication. The Zofran lawsuits currently pending claim GlaxoSmithKline concealed hundreds of birth defect reports concerning babies who were exposed to the drug in-utero.
Zofran was never approved for the treatment of pregnancy-related nausea and vomiting. Yet, one million expectant women are prescribed Zofran or its generic equivalents every year for this purpose, according to an analysis published recently in the American Journal of Obstetrics and Gynecology.
